EP4604921A1 — Sustained release injectable formulations using aprotic polar solvents
Assigned to Xeris Pharmaceuticals Inc · Expires 2025-08-27 · 1y expired
What this patent protects
The present invention concerns the use of aprotic polar solvents, water, and an ionization stabilizing agent to prepare stable therapeutic formulations, particularly sustained release formulations, of a variety of active pharmaceutical ingredients (APIs), such as, e.g., levothyro…
USPTO Abstract
The present invention concerns the use of aprotic polar solvents, water, and an ionization stabilizing agent to prepare stable therapeutic formulations, particularly sustained release formulations, of a variety of active pharmaceutical ingredients (APIs), such as, e.g., levothyroxine. In particular, the invention concerns the use of aprotic polar solvents and at least one ionization stabilizing agent to prepare stable therapeutic formulations of a variety of APIs by dissolving at least one API in an aprotic polar solvent system to produce a stable sustained release therapeutic formulation useful in treating, preventing and/or diagnosing diseases or physical disorders in humans and veterinary animals. The invention also provides methods of manufacturing such formulations.
Drugs covered by this patent
- Glucagen (GLUCAGON) · Xeris
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.